A multi-centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia.

Hdl Handle:
http://hdl.handle.net/10147/322351
Title:
A multi-centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia.
Authors:
Maung, Su W; Leahy, Maeve; O'Leary, Hilary M; Khan, Irfan; Cahill, Mary R; Gilligan, Oonagh; Murphy, Philip; McPherson, Suzanne; Jackson, Fred; Ryan, Mary; Hennessy, Brian; McHugh, Johnny; Goodyer, Matthew; Bacon, Larry; O'Gorman, Peter; Nee, Aisling; O'Dwyer, Michael; Enright, Helen; Saunders, Jean; O'Keeffe, Denis
Affiliation:
Department of Haematology, University Hospital Limerick, Limerick, Ireland; Department of Haematology, Tallaght Hospital (AMNCH), Dublin, Ireland.
Citation:
A multi-centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia. 2013, 163 (1):118-22 Br. J. Haematol.
Journal:
British journal of haematology
Issue Date:
Oct-2013
URI:
http://hdl.handle.net/10147/322351
DOI:
10.1111/bjh.12486
PubMed ID:
23909468
Additional Links:
http://onlinelibrary.wiley.com/doi/10.1111/bjh.12486/abstract
Abstract:
This retrospective analysis assessed the response, safety and duration of response to standard dose rituximab 375 mg/m(2) weekly for four weeks as therapy for patients with primary or secondary warm autoimmune haemolytic anaemia (WAIHA), who had failed initial treatment. Thirty-four patients received rituximab for WAIHA in seven centres in the Republic of Ireland. The overall response rate was 70·6% (24/34) with 26·5% (9/34) achieving a complete response (CR). The time to response was 1 month post-initiation of rituximab in 87·5% (21/24) and 3 months in 12·5% (3/24) of patients. The median duration of follow-up was 36 months (range 6-90 months). Of the patients who responded, 50% (12/24) relapsed during follow up with a median time to next treatment of 16·5 months (range 6-60 months). Three patients were re-treated with rituximab 375 mg/m2 weekly for four weeks at relapse and responded. There was a single episode of neutropenic sepsis. Rituximab is an effective and safe treatment for WAIHA but a significant number of patients will relapse in the first two years post treatment. Re-treatment was effective in a small number of patients, suggesting that intermittent pulse treatment or maintenance treatment may improve long-term response.
Item Type:
Article
Language:
en
MeSH:
Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derived; Female; Humans; Immunologic Factors; Ireland; Male; Middle Aged; Recurrence; Retrospective Studies; Treatment Outcome; Young Adult
ISSN:
1365-2141

Full metadata record

DC FieldValue Language
dc.contributor.authorMaung, Su Wen_GB
dc.contributor.authorLeahy, Maeveen_GB
dc.contributor.authorO'Leary, Hilary Men_GB
dc.contributor.authorKhan, Irfanen_GB
dc.contributor.authorCahill, Mary Ren_GB
dc.contributor.authorGilligan, Oonaghen_GB
dc.contributor.authorMurphy, Philipen_GB
dc.contributor.authorMcPherson, Suzanneen_GB
dc.contributor.authorJackson, Freden_GB
dc.contributor.authorRyan, Maryen_GB
dc.contributor.authorHennessy, Brianen_GB
dc.contributor.authorMcHugh, Johnnyen_GB
dc.contributor.authorGoodyer, Matthewen_GB
dc.contributor.authorBacon, Larryen_GB
dc.contributor.authorO'Gorman, Peteren_GB
dc.contributor.authorNee, Aislingen_GB
dc.contributor.authorO'Dwyer, Michaelen_GB
dc.contributor.authorEnright, Helenen_GB
dc.contributor.authorSaunders, Jeanen_GB
dc.contributor.authorO'Keeffe, Denisen_GB
dc.date.accessioned2014-07-03T14:05:48Z-
dc.date.available2014-07-03T14:05:48Z-
dc.date.issued2013-10-
dc.identifier.citationA multi-centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia. 2013, 163 (1):118-22 Br. J. Haematol.en_GB
dc.identifier.issn1365-2141-
dc.identifier.pmid23909468-
dc.identifier.doi10.1111/bjh.12486-
dc.identifier.urihttp://hdl.handle.net/10147/322351-
dc.description.abstractThis retrospective analysis assessed the response, safety and duration of response to standard dose rituximab 375 mg/m(2) weekly for four weeks as therapy for patients with primary or secondary warm autoimmune haemolytic anaemia (WAIHA), who had failed initial treatment. Thirty-four patients received rituximab for WAIHA in seven centres in the Republic of Ireland. The overall response rate was 70·6% (24/34) with 26·5% (9/34) achieving a complete response (CR). The time to response was 1 month post-initiation of rituximab in 87·5% (21/24) and 3 months in 12·5% (3/24) of patients. The median duration of follow-up was 36 months (range 6-90 months). Of the patients who responded, 50% (12/24) relapsed during follow up with a median time to next treatment of 16·5 months (range 6-60 months). Three patients were re-treated with rituximab 375 mg/m2 weekly for four weeks at relapse and responded. There was a single episode of neutropenic sepsis. Rituximab is an effective and safe treatment for WAIHA but a significant number of patients will relapse in the first two years post treatment. Re-treatment was effective in a small number of patients, suggesting that intermittent pulse treatment or maintenance treatment may improve long-term response.en_GB
dc.language.isoenen
dc.relation.urlhttp://onlinelibrary.wiley.com/doi/10.1111/bjh.12486/abstracten_GB
dc.rightsArchived with thanks to British journal of haematologyen_GB
dc.subject.meshAdolescent-
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAged, 80 and over-
dc.subject.meshAnemia, Hemolytic, Autoimmune-
dc.subject.meshAntibodies, Monoclonal, Murine-Derived-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshImmunologic Factors-
dc.subject.meshIreland-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshRecurrence-
dc.subject.meshRetrospective Studies-
dc.subject.meshTreatment Outcome-
dc.subject.meshYoung Adult-
dc.titleA multi-centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia.en_GB
dc.typeArticleen
dc.contributor.departmentDepartment of Haematology, University Hospital Limerick, Limerick, Ireland; Department of Haematology, Tallaght Hospital (AMNCH), Dublin, Ireland.en_GB
dc.identifier.journalBritish journal of haematologyen_GB
dc.description.fundingNo fundingen
dc.description.provinceMunsteren
dc.description.peer-reviewpeer-reviewen

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.